Drugs / CD22 CAR-T
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04626739 | Apr 2020 → Mar 2023 | non-Hodgkin lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT04626765 | Apr 2020 → Mar 2023 | childhood acute lymphoblastic leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT04626726 | Apr 2020 → May 2023 | B-cell adult acute lymphocytic leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06408194 | May 2024 → Feb 2027 expected | acute lymphoblastic leukemia | Stanford University | Recruiting | No outcome recorded |
| Phase 1 | NCT06340737 | Mar 2024 → Apr 2031 expected | Burkitt lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma, hairy cell leukemia +3 | Stanford University | Recruiting | No outcome recorded |
| Phase 1 | NCT04815356 | May 2022 → Dec 2036 expected | hairy cell leukemia variant | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02794961 | Jun 2016 → Jun 2018 | B-cell neoplasm | Kai Lin Xu; Jun Nian Zheng | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04546906 | Sep 2020 → Sep 2022 | — | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD22 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04626765 ↗ |
| Modality | Cell therapy | “Autologous CAR-T cells with average 1\*10\^6 cells/kg body weight” NCT02794961 ↗ |
| Target | CD22 | “target CD22 molecule on B cells” NCT02794961 ↗ |